Trial Profile

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Aalum Adjuvants and VRC HIV Env Trimer 4571 and 3M-052-AF With Alum in Healthy, HIV-uninfected Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BG505 SOSIP 664 gp140 adjuvanted vaccine (Primary) ; Aluminium hydroxide
Indications HIV infections
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

04 Dec 2024 Status changed from active, no longer recruiting to completed.
09 Jun 2023 Planned End Date changed from 17 Jul 2023 to 4 Nov 2024.
09 Jun 2023 Planned primary completion date changed from 17 Jul 2023 to 4 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com